Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 8 Jul 2026

Mazzitelli Maria, Parczewski Milosz, Burger David, Wensing Annemarie

Abstract excerpt

BACKGROUND: Virological failure (VF) with long-acting injectable cabotegravir and rilpivirine (CAB/RPV-LA) is uncommon but often associated with selection of resistance, potentially limiting future treatment options. Registration trials associated VF risk with baseline RPV resistance, A1/A6 subtypes, and body mass index (BMI) >30 kg/m2, but these factors have rarely been analyzed in other clinical settings. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to Pyridones

Share to Rilpivirine

Share to Risk Factors

Share to Treatment Failure

Source

Identifiers

PMID: 41811386
DOI: 10.1093/cid/ciag046

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications.PMID 41811386Read ↗

Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.Semantic proximity Read ↗

Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patientsSemantic proximity Read ↗

Virological failure and resistance emergence during treatment with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine in people living with HIV without prior resistance mutations: a real-world study.Semantic proximity Read ↗

Drug Resistance Mutations (DRMs) for Long-Acting Injectable Cabotegravir and Rilpivirine (CAB/RPV LAI) in the HIV-1 Subtype A6 Epidemic in PolandSemantic proximity Read ↗

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.Semantic proximity Read ↗

HIV-1 virologic failure in the RESINA cohort: lessons from two decades of real-world data.Semantic proximity Read ↗

Evaluation of HIV-1 drug resistance in newly diagnosed individuals in Italy over the period 2017-2023.Semantic proximity Read ↗

HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018–2024Semantic proximity Read ↗

Factors associated with virological failure in people with HIV treated with bictegravir/emtricitabine/tenofovir alafenamide. Impact of pre-existing mutations and risk of resistance emergence. ANRS-CO3-AquiVIH-NA cohort.Semantic proximity Read ↗

96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.Semantic proximity Read ↗

[Drug resistance characteristics of rilpivirine in HIV-1-infected patients before starting antiretroviral therapy in nine provinces of China].Semantic proximity Read ↗

Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.